Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study

References

• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–18. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M. Human papillomavirus–Associated Cancers — United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–66. doi:10.15585/mmwr.mm6526a1.
   PubMed Web of Science ®Google Scholar
• Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol. 2019;37(18):1538–46. doi:10.1200/JCO.19.00370.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:630–32. [accessed 2020 Jan 30].
   PubMedGoogle Scholar
• Food and Drug Administration. Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18]). Silver Spring, MD: Food and Drug Administration; 2011. accessed 2020 Jan 30.
   Google Scholar
• Centers for Disease Control. Recommendations on the use of quadrivalent human papillomavirus vaccine in males – advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705–08. [accessed 2020 Jan 30].
   PubMedGoogle Scholar
• Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140–48. doi:10.1001/archpediatrics.2012.1451.
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley M, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29(46):8279–84. doi:10.1016/j.vaccine.2011.08.106.
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun M, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Jama. 2009;302(7):750–57. doi:10.1001/jama.2009.1201.
   PubMed Web of Science ®Google Scholar
• Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34(9):983–91. doi:10.1097/INF.0000000000000793.
   PubMed Web of Science ®Google Scholar
• Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf. 2015;14(5):697–712. doi:10.1517/14740338.2015.1013532.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11. doi:10.1056/NEJMoa0909537.
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. HCUP research tools and software. Healthcare Cost and Utilization Project (HCUP); 2022 [accessed 2022 April 8]. https://www.hcup-us.ahrq.gov/toolssoftware/ccs/CCSCategoryNames_FullLabels.pdf .
   Google Scholar
• Mehrotra DV, Heyse JF. Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res. 2004;13(3):227–38. doi:10.1191/0962280204sm363ra.
   PubMed Web of Science ®Google Scholar
• National Technical Information Service. Social security administration death master file; 2020 [accessed 2020 Jan 29]. https://dmf.ntis.gov/ .
   Google Scholar
• Centers for Disease Control. National Death Index; 2017 [accessed 2020 Jan 29]. https://www.cdc.gov/nchs/ndi/index.htm .
   Google Scholar
• ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200–08. doi:10.1002/pds.1471.
   PubMed Web of Science ®Google Scholar
• Amend KL, Turnbull B, Zhou L, Marks MA, Velicer C, Saddier P, Seeger JD. Vaccine initiation and 3-dose series completion of 4vhpv vaccine among US insured males 2012-2016. Vaccine. 2022;40(4):682–88. doi:10.1016/j.vaccine.2021.10.070.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Deaths_ final data for 2016. National Vital Statistics Reports (Vol 67, No 5). 2018 Jul 26.
   Google Scholar
• Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, vaccine safety datalink, 2008-2011. Vaccine. 2016;34(1):167–71. doi:10.1016/j.vaccine.2015.10.006.
   PubMed Web of Science ®Google Scholar
• Frisch M, Besson A, Clemmensen KKB, Valentiner-Branth P, Mølbak K, Hviid A. Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. Int J Epidemiol. 2018;47(2):634–41. doi:10.1093/ije/dyx273.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine.Adverse effects of vaccines. 2011.http://www.nationalacademies.org/hmd//media/Files/Report%20Files/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality/Vaccine-report-brief-FINAL.pdf .
   Google Scholar
• Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. New South wales health HPV adverse events panel. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008 Sep 9;179(6):525–33. doi:10.1503/cmaj.080916.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37. doi:10.1016/j.jclinepi.2004.10.012.
   PubMed Web of Science ®Google Scholar
• Seeger JD. Commercial databases. In SB, editor. Pharmacoepidemiology. 5 ed. Chicester, UK: Wiley; 2012. pp. 189–208.
   Google Scholar
• Ferver K. The use of claims data in healthcare research. 2009 [accessed 2020 Jan 30]. https://openpublichealthjournal.com/contents/volumes/V2/TOPHJ-2-11/TOPHJ-2-11.pdf .
   Google Scholar